Caricamento...
Adding chimeric antigen receptor–induced killer cells to the medical oncology shelf
With the approval of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatment of B cell malignancies, clinicians have gained valuable insights into the power and challenges of cellular therapies. In this issue of the JCI, Maluski et al. showed that a CAR containing a CD28 costimulator...
Salvato in:
| Pubblicato in: | J Clin Invest |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6877296/ https://ncbi.nlm.nih.gov/pubmed/31638599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132536 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|